A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 2002

Conditions

HIV Infections

Interventions

BIOLOGICAL

HIV-1 C4-V3 Polyvalent Peptide Vaccine

Trial Locations (1)

Duke Univ Med Ctr, Durham

All Listed Sponsors

collaborator

Lederle-Praxis Biologicals

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001060 - A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons | Biotech Hunter | Biotech Hunter